Claims for Patent: 8,802,702

Summary for Patent: 8,802,702

Title:	Compounds for reducing drug resistance and uses thereof
Abstract:	This invention provides compounds capable of reducing drug resistance in a subject undergoing cancer treatment, methods using the compounds, compositions, and methods for identifying such compounds.
Inventor(s):	Duan; Zhenfeng (Cambridge, MA), Hornicek; Francis J. (Burlington, MA)
Assignee:	The General Hospital Corporation (Boston, MA)
Application Number:	13/144,228
Patent Claims:	1. A method of reducing drug resistance in a subject undergoing cancer treatment with administration of a chemotherapeutic drug, wherein the cancer is selected from the group consisting of: breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, head and neck, thyroid, parathyroid, a distant metastasis of a solid tumor, lymphoma, sarcoma, and leukemia, said method comprising administering to a subject in need thereof an effective amount of (2-(4-Methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol or a pharmaceutically acceptable salt thereof, wherein (2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol or a pharmaceutically acceptable salt thereof is administered at a dose that is lower than the dose required to produce cytotoxicity in said subject, thereby reducing drug resistance in said subject. 2. The method of claim 1, wherein (2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol or a pharmaceutically acceptable salt thereof is administered to said subject at a dose at least 10 fold lower than that required to produce cytotoxicity in said subject. 3. The method of claim 2, wherein (2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol or its pharmaceutically acceptable salt thereof is administered to said subject at a dose at least 50 fold lower than that required to produce cytotoxicity in said subject. 4. The method of claim 1, wherein (2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol or a pharmaceutically acceptable salt thereof is administered to said subject at a dose between about 0.001 mg/Kg and about 100 mg/Kg. 5. The method of claim 1, wherein (2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol or a pharmaceutically acceptable salt thereof is administered to said subject after the administration of said chemotherapeutic drug. 6. The method of claim 1, wherein said chemotherapeutic drug is selected from the group consisting of asparaginase, bleomycin, calcein-AM, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin (adriamycine), epirubicin, etoposide, ET-743, 5-fluorouracil, gemcitabine, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, paclitaxel, prednisolone, prednisone, procarbazine, raloxifen, rhodamine-123, streptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, vindesine, and zalypsis. 7. A method for treating cancer in a subject, wherein the cancer is selected from the group consisting of: breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, head and neck, thyroid, parathyroid, a distant metastasis of a solid tumor, lymphoma, sarcoma, and leukemia, said method comprising a) identifying a subject undergoing cancer treatment with a chemotherapeutic drug and who has developed or is susceptible to developing drug resistance; and b) administering to said subject an effective amount of (2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol or a pharmaceutically acceptable salt thereof, wherein said effective amount is sufficient to reduce drug resistance in said subject, thereby treating cancer in a subject. 8. The method of claim 7, wherein said method further comprises discontinuing said cancer treatment. 9. The method of claim 8, wherein said cancer treatment is discontinued prior to the administration of (2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol or a pharmaceutically acceptable salt thereof. 10. The method of claim 8, wherein said cancer treatment is discontinued after the administration of (2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol or a pharmaceutically acceptable salt thereof. 11. The method of claim 8, wherein said method further comprises administering to said subject a subsequent cancer treatment after the discontinuation of said cancer treatment and the administration of (2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol or a pharmaceutically acceptable salt thereof. 12. The method of claim 11, wherein said subsequent cancer treatment is the same as said discontinued cancer treatment. 13. The method of claim 11, wherein said subsequent cancer treatment is different from said discontinued cancer treatment. 14. The method of claim 11, further comprising administering to said subject an additional effective amount of (2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol or a pharmaceutically acceptable salt thereof after administration of said subsequent cancer treatment. 15. The method of claim 1, wherein the cancer is an ovarian cancer. 16. The method of claim 1, wherein the cancer is a breast cancer. 17. The method of claim 1, wherein the cancer is a leukemia. 18. The method of claim 1, wherein the cancer is a brain cancer. 19. The method of claim 1, wherein the cancer is a thyroid cancer. 20. The method of claim 7, wherein the cancer is an ovarian cancer. 21. The method of claim 7, wherein the cancer is a breast cancer. 22. The method of claim 7, wherein the cancer is a leukemia. 23. The method of claim 7, wherein the cancer is a brain cancer.

Details for Patent 8,802,702

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2029-01-15